<DOC>
	<DOC>NCT00889070</DOC>
	<brief_summary>Assess the burden of disease associated with RSV infection with premature children in an outpatient setting.</brief_summary>
	<brief_title>Respiratory Events Among Premature Infants</brief_title>
	<detailed_description>The primary objective of this prospective study is to assess the burden of disease associated with RSV infection, as measured/determined by rates of outpatient medically attended LRI, emergency room visits and hospitalization among preterm infants (32-≤36 wGA) during RSV season, and its medical/health consequences, as measured by wheezing events, the infant's first RSV season, up to May 2009.</detailed_description>
	<criteria>Written informed consent from parent/guardian to participate in study Male or female preterm infants 32≤36 wGA Infant is ≤ 6month old at the time of enrollment Parent/guardian has the ability and willingness to follow study protocol (during the first RSV season) as required by the protocol Receipt of any RSV prophylactic agent: palivizumab, IGIV, or motavizumab at any time prior to enrollment Participation in trials of investigational RSV prophylaxis or RSV therapeutic agents Presence of BPD or CHD (other than surgically treated PDA, ASD or VSD) Condition that limits life span to 6 months or less from the date of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>